• Nanjing Leads Biolabs moved a Phase II study of Opamtistomig with bevacizumab in first-line liver cancer into the expansion phase on Aug. 5, 2026.
• Early results were presented as preliminary clinical data, showing encouraging anti-tumor activity with a favorable safety profile.
• The expansion phase advances the program toward broader clinical validation in a first-line setting dominated by PD-1/PD-L1 combinations with bevacizumab.
• Opamtistomig is a PD-L1/4-1BB bispecific antibody designed to activate 4-1BB signaling in tumors, positioned as a next-generation immunotherapy platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608052053PRIMZONEFULLFEED9804851) on August 06, 2026, and is solely responsible for the information contained therein.